NEWS
undefined

undefined

Jiudian Scholarship Donation Ceremony was held in Xiangtan University

Jiudian Scholarship Donation Ceremony was held in Xiangtan University

On the occasion of the 50th anniversary of Xiangtan University's re-establishment, Jiudian Pharmaceutical donated 250,000 yuan to Xiangtan University and injected it into the "Xiangtan University Jiudian Pharmaceutical Scholarship Fund" to support poverty students in the School of Chemistry.

21

2024

/

03

Hunan Jiudian Pharmaceutical have Market Authorization of Potassium Sulphate API from NMPA

Hunan Jiudian Pharmaceutical have Market Authorization of Potassium Sulphate API from NMPA

In the middle of March, 2024, Jiudian Hongyang Pharmaceutical, which is wholly-owned subsidiary of Jiudian Pharmaceutical, have market authorization of Potassium Sulphate API from NMPA.

18

2024

/

03

Hunan Jiudian Pharmaceutical have Ecovadis Bronze at the beginning of 2024

Hunan Jiudian Pharmaceutical have Ecovadis Bronze at the beginning of 2024

On March 1, 2024, Jiudian Hongyang Pharmaceutical, which is wholly-owned subsidiary of Jiudian Pharmaceutical, focus on production of APIs and excipients, have Ecovadis score for the first time, it is Bronze.

06

2024

/

03

Jiudian Pharmaceutical signed a patent and technology transfer agreement for LPS/CD 14 dual-target spot polypeptide new drug with Zonsen Peplib Biotech.

Jiudian Pharmaceutical signed a patent and technology transfer agreement for LPS/CD 14 dual-target spot polypeptide new drug with Zonsen Peplib Biotech.

Jiudian Pharmaceutical signed a patent and technology transfer agreement for LPS/CD 14 dual-target spot polypeptide new drug with Zonsen PepLib Biotech in Changsha China on Feb 28, 2024.

29

2024

/

02

Hunan Jiudian Pharmaceutical have Market Authorization of dapoxetine hydrochloride, celecoxib and Nicorandil API from NMPA

Hunan Jiudian Pharmaceutical have Market Authorization of dapoxetine hydrochloride, celecoxib and Nicorandil API from NMPA

In Feb, 2024, Jiudian Hongyang Pharmaceutical, which is wholly-owned subsidiary of Jiudian Pharmaceutical, have market authorization of dapoxetine hydrochloride and celecoxib API from NMPA.

03

2024

/

02

Jiudian Pharmaceutical have drug license of Ebastine oral solution from NMPA

Jiudian Pharmaceutical have drug license of Ebastine oral solution from NMPA

At the beginning of 2024, PudaoPharma, which is wholly-owned subsidiary of Jiudian Pharmaceutical, had drug license of Ebastine oral solution from NMPA. PudaoPharma is the first enterprise to obtain this dosage form license of Ebastine in China.

01

2024

/

02

Hunan Jiudian Pharmaceutical have Market Authorization of Methyl Salicylate and Sodium Sulfate APIs from NMPA

Hunan Jiudian Pharmaceutical have Market Authorization of Methyl Salicylate and Sodium Sulfate APIs from NMPA

In Jan, 2024, Jiudian Hongyang Pharmaceutical, which is wholly-owned subsidiary of Jiudian Pharmaceutical, have market authorization of Methyl Salicylate and Sodium Sulfate APIs from NMPA.

24

2024

/

01

Ketoprofen Cataplasms authorized by National Healthcare Security Administration, on NRDL

Ketoprofen Cataplasms authorized by National Healthcare Security Administration, on NRDL

At the end of 2023, National Healthcare Security Administration announced the results of the adjustment of NRDL (The National Reimbursement Drug List, NRDL was introduced in 2000 to support medical healthcare and providing patients with basic medical treatments.), there are 126 drugs newly added. Jiudian Pharmaceutical's exclusive dosage form Ketoprofen Cataplasms is one of them. The new NRDL will be officially implemented on January 1, 2024.

13

2023

/

12

< 1...6789 >

Bldg A1, Wukuang Lugu Science and Technology Industry Park, No.28 Lutian Road, Hi-tech development zone, Changsha, Hunan, China     TEL. 0086-731-88220222     

1

Business license

SEO www.300.cn  changsha   Privacy policy